Nuritas Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
73
- Latest Deal Type
-
2ndary - Private
- Investors
-
20
Nuritas General Information
Description
Developer of a biotechnology platform designed to extract peptides from food sources. The company's platform combines artificial intelligence and genomics to discover and unlock natural bioactive peptides with health benefits, enabling businesses to make the food system more sustainable by replacing unwanted ingredients and molecules with more natural and sustainable ones.
Contact Information
Website
www.nuritas.comCorporate Office
- Joshua Dawson House
- Dawson Street
- Dublin D02 RY95
- Ireland
Corporate Office
- Joshua Dawson House
- Dawson Street
- Dublin D02 RY95
- Ireland
Nuritas Timeline
Nuritas Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 13. Accelerator/Incubator | 01-Jan-2026 | Completed | Generating Revenue | |||
| 12. Accelerator/Incubator | 08-Jul-2025 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series C) | 20-Dec-2024 | Completed | Generating Revenue | |||
| 10. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 9. Secondary Transaction - Private | 02-Nov-2022 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series B) | 11-Nov-2021 | Completed | Generating Revenue | |||
| 7. Debt - General | 28-Nov-2018 | Completed | Generating Revenue | |||
| 6. Early Stage VC (Series A) | 21-Dec-2017 | $18.5M | $23.8M | Completed | Generating Revenue | |
| 5. Seed Round | 07-Dec-2016 | $2.07M | $5.35M | Completed | Generating Revenue |
Nuritas Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series B | ||||||||
| Series B | ||||||||
| Series A1 | ||||||||
| Series A | 30,114 | $0.001159 | $107.55 | $107.55 | 1x | $107.55 | 5.14% | |
| Ordinary | 19,000 | $0.001159 | $1.16 | $1.16 | 1x | $1.16 | 3.24% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Nuritas Comparisons
Industry
Financing
Details
Nuritas Competitors (4)
One of Nuritas’s 4 competitors is Abcam, a Corporate Backed or Acquired company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abcam | Corporate Backed or Acquired | Cambridge, United Kingdom | ||||
| Charles River Laboratories International | Formerly PE-Backed | Wilmington, MA | ||||
| Q Laboratories | Private Equity-Backed | Cincinnati, OH | ||||
| Apeptico | Formerly VC-backed | Vienna, Austria |
Nuritas Patents
Nuritas Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4828704-A2 | Angiotensin-converting enzyme (ace) inhibiting peptides | Pending | 20-Dec-2023 | ||
| AU-2024405811-A1 | Angiotensin-converting enzyme (ace) inhibiting peptides. | Pending | 20-Dec-2023 | ||
| WO-2025133254-A2 | Angiotensin-converting enzyme (ace) inhibiting peptides. | Inactive | 20-Dec-2023 | ||
| WO-2025133254-A3 | Angiotensin-converting enzyme (ace) inhibiting peptides. | Inactive | 20-Dec-2023 | ||
| AU-2024402215-A1 | Sleep promoting peptides and the use thereof | Pending | 20-Dec-2023 | C07K7/06 |
Nuritas Signals
Nuritas Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Plug and Play | Accelerator/Incubator | |||
| pladis Foods | Accelerator/Incubator | Minority | ||
| McWin Capital Partners | PE/Buyout | Minority | ||
| M&G | Asset Manager | Minority | ||
| CJ | Corporation | Minority |
Nuritas Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Nuritas Uk | London, United Kingdom | 2018 |
Nuritas FAQs
-
When was Nuritas founded?
Nuritas was founded in 2014.
-
Where is Nuritas headquartered?
Nuritas is headquartered in Dublin, Ireland.
-
What is the size of Nuritas?
Nuritas has 73 total employees.
-
What industry is Nuritas in?
Nuritas’s primary industry is Discovery Tools (Healthcare).
-
Is Nuritas a private or public company?
Nuritas is a Private company.
-
What is Nuritas’s current revenue?
The current revenue for Nuritas is .
-
How much funding has Nuritas raised over time?
Nuritas has raised $150M.
-
Who are Nuritas’s investors?
Plug and Play, pladis Foods, McWin Capital Partners, M&G, and CJ are 5 of 20 investors who have invested in Nuritas.
-
Who are Nuritas’s competitors?
Abcam, Charles River Laboratories International, Q Laboratories, and Apeptico are competitors of Nuritas.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process